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Abstract: Abstract
Background
Aortic valve replacement is one of the most common cardiac surgical procedures
performed worldwide. Conventional aortic valve replacement surgery is performed via
a median sternotomy; the sternum is divided completely from the sternal notch to the
xiphisternum. Minimally invasive aortic valve replacement, using a new technique
called manubrium-limited ministernotomy, divides only the manubrium from the sternal
notch to 1cm below the manubrio-sternal junction.
Over one third of patients undergoing conventional sternotomy develop clinically
significant bleeding requiring post-operative red blood cell transfusions. Case series
data suggest a potentially clinically significant difference in red blood cell transfusion
requirements between the two techniques. Given the implications for NHS resources
and patient outcomes, a definitive trial is needed.
Design
This is a single centre, single blind, randomised controlled trial, comparing aortic valve
replacement surgery using manubrium-limited ministernotomy (intervention) and
conventional median sternotomy (usual care). Two hundred and sixty patients will be
randomised in a 1:1 ratio between the intervention and control arms, stratified by
baseline logistic EuroSCORE and haemoglobin value. Patients will be followed for 12
weeks from discharge following their index operation. The primary outcome is the
proportion of patients who receive a red blood cell transfusion post-operatively within 7
days of surgery. Secondary outcomes include red blood cell and blood product
transfusions, blood loss, re-operation rates, sternal wound pain, quality of life, markers
of inflammatory response, hospital discharge, health care utilisation, cost and cost
effectiveness, and adverse events.
Discussion
This is the first trial to examine aortic valve replacement via manubrium-limited
ministernotomy versus conventional sternotomy when comparing red blood cell
transfusion rates following surgery. Surgical trials present significant challenges;
strengths of this trial include a rigorous research design, standardised surgery
performed by experienced consultant cardiothoracic surgeons, an agreed anaesthetic
regimen, patient blinding, and consultant-led patient recruitment. The MAVRIC trial will
demonstrate that complex surgical trials can be delivered to exemplary standards and
provide the community with the knowledge required to inform future care for patients
requiring aortic valve replacement surgery.
Corresponding Author: Helen C Hancock, PhD
UNIVERSITY OF DURHAM
Stockton on Tees, UNITED KINGDOM
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Corresponding Author Secondary
Information:
Corresponding Author's Institution: UNIVERSITY OF DURHAM
Corresponding Author's Secondary
Institution:
First Author: Enoch Akowuah, MD
First Author Secondary Information:
Order of Authors: Enoch Akowuah, MD
Andrew T Goodwin, PhD
W Andrew Owens, MD
Helen C Hancock, PhD
Rebecca Maier, MSc
Adetayo Kasim, PhD
Adrian Mellor, MD
Khalid Khan, MD
Gavin Murphy, MD
James M Mason, DPhil
Order of Authors Secondary Information:
Response to Reviewers: Tianjing Li,
Senior Editor, Trials
Dear Tianjing Li,
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Manubrium-limited ministernotomy versus conventional sternotomy for aortic valve
replacement: randomised controlled trial protocol (MAVRIC) Enoch Akowuah, MD;
Andrew T Goodwin, PhD; W Andrew Owens, MD; Helen C Hancock, PhD; Rebecca
Maier, MSc; Adetayo Kasim, PhD; Adrian Mellor, MD; Khalid Khan, MD; Gavin Murphy,
MD; James M Mason, DPhil Trials
Many thanks for your recent correspondence regarding our paper. The research team
has answered each of your comments in turn as well as those of the reviewer.
We have reviewed guidance regarding preparation of the paper alongside recently
published protocols and hope the format is acceptable.
If anything below or in the paper is unclear, please do not hesitate to let us know.
Sincerely,
Helen Hancock (on behalf of the MAVRIC trial team)
 
Response to Reviewers:
Editor's comments:
1. Please specify your primary and secondary outcomes fully following the 5 elements
as described in paper Zarin NEJM 2011l364:852-60.
We have amended these in the paper, using tracked changes. In doing so we have
reviewed the paper (above) as well as protocols recently published in Trials.
2. Please address the reviewer's comments.
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We can confirm that we have reviewed and addressed the single reviewers comments;
these are addressed in the paper, using tracked changes, and detailed below.
3. Did you upload a SPIRIT checklist?
We can confirm that a SPIRIT checklist has now been included
Reviewer #1:
The author proposed a randomized controlled trial to compare the outcome of aortic
valve replacement surgery using manubrium-limited ministernotomy (intervention) and
conventional median sternotomy (usual care). The result from the trial is important
given that the surgery is commonly performed. However, the author was not very clear
in the primary and secondary outcomes, and need to provide more information
regarding the two procedures in the background. Additionally, the author should adopt
more appropriate statistical models for analyzing the data. Some more specific
comments:
1. It's not very clear to me if the manubrium-limited ministernotomy is comparable to
conventional median sternotomy in serving the purpose of aortic valve replacement.
For example, is the success rate of the two procedures similar? What about survival?
Is there specific indications in patients that make one procedure more preferable?
What's the advantage and disadvantage of both procedures? The author can introduce
more about it in the background.
The trial compares two surgical approaches to gaining access to the heart for the
purpose of aortic valve replacement surgery. The trial is not studying AVR per se. The
two approaches in the trial are: manubrium-limited ministernotomy (intervention) and
conventional median sternotomy (usual care); both are commonly performed in the
NHS and are known to be successful and safe. The main aim of the trial is to ascertain
any impact of the surgical approach on the need for red blood cell transfusion in the
post-operative period. The trial is funded by the NIHR.
2. Is there criteria for modifying the allocated interventions for a given participant (eg,
worsening of disease)?
No. These patients require a single surgical intervention to replace their aortic valve.
Inclusion criteria state that all patients should be eligible for both surgical approaches.
Recruitment timelines mean that the disease state is unlikely to worsen following
confirmation of eligibility and date of surgery.
3. The primary and secondary outcomes are confusing and sometimes switched. For
example, in page 15, the proportion of patients who receive a red blood cell transfusion
was listed as both primary and secondary outcome. Need to be more specific and
clear.
We have added details to the paper as requested, including timelines for data capture.
4. For the sample size, can you justify how you come up with 17% reduction? It seems
to be a very optimistic estimation of the intervention effect.
An audit of 110 patients conducted in advance of designing the trial indicated 30% of
patients receiving conventional AVR surgery required a red blood cell transfusion
compared with 13% of patients undergoing manubrium-limited ministernotomy. It is on
this that the reduction of 17% is based.
5. Analysis of the primary endpoint should be done more systematically and not only
using Fisher's exact test. Since the proportion of people receiving blood transfusion is
high, poisson regression or prevalence ratio derived from logistic regression is more
appropriate. Although it's a randomized controlled trial, adjusting for potential
confounders is still necessary.
We do not consider it appropriate to use Poisson regression or prevalence ratio to
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
analyse the binary endpoint given that the primary endpoint is whether a patient
received a blood transfusion or not. Poisson regression might be more appropriate had
the primary endpoint been count data, for example, the number of times each patient
received a blood transfusion. We plan to adjust for potential confounders and
stratification variables in a logistic regression model as a sensitivity analysis for the
primary endpoint. This has been made explicit in the protocol.
6. Add statement of who will have access to the final trial data and disclosure of
contractual agreements that limit such access to investigators
The main contract is the standard used across all NIHR projects; this contains standard
clauses relating to data confidentiality, data protection and rights to data. All members
of the research team, including investigators and trial statisticians, will have access to
the trial data.
7. Provide informed consent materials as appendices.
We have noted that this is not a specific requirement of the journal, and that other
published protocols do not include this. If journal editors would like to discuss it’s
inclusion we would be happy to consider this request.
8. Abstract back ground. "Aoritic valve replacement is one on the most" should be "one
of the"
Thank you, we have made the alteration in the paper.
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Abstract 
 
Background 
Aortic valve replacement is one ofn the most common cardiac surgical procedures 
performed worldwide. Conventional aortic valve replacement surgery is performed 
via a median sternotomy; the sternum is divided completely from the sternal notch to 
the xiphisternum. Minimally invasive aortic valve replacement, using a new technique 
called manubrium-limited ministernotomy, divides only the manubrium from the 
sternal notch to 1cm below the manubrio-sternal junction. 
 
Over one third of patients undergoing conventional sternotomy develop clinically 
significant bleeding requiring post-operative red blood cell transfusions. Case series 
data suggest a potentially clinically significant difference in red blood cell transfusion 
requirements between the two techniques. Given the implications for NHS resources 
and patient outcomes, a definitive trial is needed.  
 
Methods/dDesign 
This is a single centre, single blind, randomised controlled trial, comparing aortic valve 
replacement surgery using manubrium-limited ministernotomy (intervention) and 
conventional median sternotomy (usual care). Two hundred and seventy patients will 
be randomised in a 1:1 ratio between the intervention and control arms, stratified by 
baseline logistic EuroSCORE and haemoglobin value. Patients will be followed for 12 
weeks from discharge following their index operation. The primary outcome is the 
proportion of patients who receive a red blood cell transfusion post-operatively within 
7 days of surgery. Secondary outcomes include red blood cell and blood product 
transfusions, blood loss, re-operation rates, sternal wound pain, quality of life, markers 
of inflammatory response, hospital discharge, health care utilisation, cost and cost 
effectiveness, and adverse events.  
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Discussion 
This is the first trial to examine aortic valve replacement via manubrium-limited 
ministernotomy versus conventional sternotomy when comparing red blood cell 
transfusion rates following surgery. Surgical trials present significant challenges; 
strengths of this trial include a rigorous research design, standardised surgery 
performed by experienced consultant cardiothoracic surgeons, an agreed 
anaesthetic regimen, patient blinding, and consultant-led patient recruitment. The 
MAVRIC trial will demonstrate that complex surgical trials can be delivered to 
exemplary standards and provide the community with the knowledge required to 
inform future care for patients requiring aortic valve replacement surgery.  
 
Trial Registration 
International Standard Randomized Controlled Trial Number (ISRCTN) 
ISRCTN29567910, registered on 3 February 2014. 
 
Keywords 
Aortic Valve Replacement (AVR); Manubrium-limited ministernotomy; Minimally 
invasive aortic valve replacement; Sternotomy; Red Blood Cell transfusion; 
Inflammatory Response 
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Background and rRationale 
 
Aortic Valve Replacement (AVR) 
AVR is one of the most common cardiac surgical procedures performed worldwide 
(1, 2). Patients suffer symptoms of chest pain, shortness of breath and dizziness as a 
result of aortic stenosis or regurgitation. Nearly 10,000 patients undergo AVR surgery in 
the United Kingdom every year (2). Patient outcomes of AVR performed in the UK 
from 2004 to 2009 were recently published (3) showing a 26% increase in the number 
of patients undergoing this surgery during this period. At The James Cook University 
Hospital (JCUH) in the North of England, an audit over the same time period 
confirmed a 24% increase in the number of AVR operations. It is anticipated that the 
number of AVR operations will continue to increase.  
 
Blood Transfusion Following AVR 
There is significant morbidity associated with AVR surgery. Consequently, blood loss 
and the subsequent requirement for transfusion of red blood cells (RBCs) and blood 
products are key indicators of quality. Over one third of patients undergoing 
conventional sternotomy develop clinically significant bleeding and require a post-
operative RBC transfusion (4,5). Blood transfusion can have adverse clinical effects 
including post-operative lung injury, organ dysfunction, confusion, and 
immunosuppression (6); complications of transfusion have been directly linked to 
prolonged hospital stay and increased mortality after cardiac surgery (5, 7-12). 
Additionally, there is a small risk of transmitting viral infection from blood donor to 
recipient (13). Currently cardiac surgical procedures use 6% of all donor blood 
available in the UK (14). An analysis of patients over 5 years from the Society for 
Cardiothoracic Surgery in Great Britain and Ireland National database indicated that 
of 41,227 patients who underwent AVR surgery 2,342 (6%) required a second 
operation due to excessive bleeding (3).   
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Retrospective studies have shown that blood loss and transfusion requirements are 
significantly less with minimally invasive AVR (15-17); however, most reported using a 
4th space ministernotomy incision rather than manubrium-limited approach. No study 
thus far has tested red blood cell transfusion requirements in a randomised controlled 
trial using manubrium-limited ministernotomy. 
 
Rationale for cChoice of cComparators  
Surgical tTechniques in AVR 
Usual Care: Conventional Sternotomy: 
Conventional surgery for AVR is performed via a median sternotomy, in which the 
sternum is divided completely from the sternal notch to the xiphisternum. The 
operation includes cardiopulmonary bypass established by siting cannulas in the right 
atrium and ascending aorta. The heart is stopped and the valve is replaced. 
Intervention Under Study: Minimally Invasive Ministernotomy: 
The new technique of manubrium-limited ministernotomy, divides only the top quarter 
of the sternum from the sternal notch to 1cm below the manubrio-sternal junction; this 
enables access to perform the AVR. Potential benefits may include reductions in 
bleeding, post-operative pain, inflammatory response, hospital stay, and time away 
from work. The cardiothoracic surgical community are enthusiastic about the 
procedure; however they are clear that definitive benefit needs to be demonstrated 
in a randomised controlled trial before widespread adoption of the technique. 
 
Inflammatory Markers 
In minimally invasive cardiac surgical procedures, there is less tissue trauma and the 
right atrium is not directly cannulated; conversely the duration of cardiopulmonary 
bypass time and aortic cross clamp are longer. The mechanism for any observed 
benefits of the minimally invasive approach is unconfirmed, but may be due to a 
difference in systemic inflammatory response (SIR). SIR can be measured by 
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monitoring the profile of non-terminal pro-hormone brain natriuretic peptide (NT-
proBNP) and cytokines in plasma. Brain natriuretic peptide (BNP) release is a marker 
of myocardial stress, myocardial damage and systemic inflammation (18).  
 
This trial will determine if there is a difference in systemic inflammatory response to 
AVR via manubrium-limited ministernotomy when compared to conventional 
sternotomy by measuring inflammatory markers (NT-proBNP and cytokines) at pre and 
post-surgical time-points. We will seek to understand the mechanism underlying the 
observations we make. Our hypothesis is that patients who receive a sternotomy will 
bleed more and require more blood transfusions. The excess bleeding might be 
directly because of the increased surgical trauma or as a result of an increased 
systemic inflammatory response to sternotomy. A systematic inflammatory response 
may have wide-ranging post-operative effects and has previously been shown to 
increase atrial fibrillation, acute kidney injury, impair wound healing and reduce post-
operative haemostasis (189). 
 
 
Trial rRationale 
Case series data at The JCUH suggest a potentially significant and clinically important 
difference in the need for red blood cell transfusion when comparing patients 
undergoing conventional and manubrium-limited surgery. Given the implications of 
transfusion for NHS resources and patient outcomes, and the potential benefits from 
this new technique, there is a need for a definitive trial. There has been one trial in the 
UK evaluating the 4th space median (minimally invasive) sternotomy (PB-PG-0408-
16296; ISRCTN 58128724); this is now closed to recruitment and in follow-up. Thus far, 
no randomised trial has compared manubrium-limited to conventional AVR.  
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The need for AVR is increasing and, with an ageing population, the balance of 
surgical risk will become less favourable given the greater level of co-morbidity in 
older populations. Importantly, this new approach also has the potential to reduce 
the risk of post-operative lung injury, organ dysfunction, and immunosuppression, as 
well as reducing the burden on already overstretched blood transfusion services. A 
robust trial of the manubrium-limited technique compared with conventional surgery 
is imperative and timely to ensure that appropriate surgical strategies deliver 
improved patient outcomes and efficient use of scarce NHS resources. 
 
The trial will run according to the principles of ICH GCP, and in accordance with 
relevant UK legislation and the Protocol.  
 
Objectives 
This trial will investigate whether new manubrium-limited surgery (intervention) 
reduces red blood cell transfusion rates compared to conventional cardiac surgery 
(control) for patients undergoing aortic valve replacement. The null hypothesis is that 
there will be no difference in the proportion of patients receiving red blood cell 
transfusion after manubrium limited ministernotomy when compared to conventional 
sternotomy for AVRrates between intervention and control groups.  
 
Trial Design 
A single centre, single-blind, randomised controlled superiority trial comparing 
patients undergoing aortic valve replacement (AVR) via manubrium-limited 
ministernotomy (intervention under study) or conventional median sternotomy 
(control arm/usual care); randomization will be performed using blocks with a 1:1 
allocation.  
 
Trial Setting  
The study aims to recruit 270 patients in a single NHS Trust in the North of England.  
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Eligibility Criteria 
Inclusion Criteria  
Patients are eligible for the study if they:  
1. are aged 18 years or over at the time of consent;  
2. require first-time, non-emergency, isolated Aortic Valve Replacement surgery; and  
3. are able and willing to provide written informed consent.  
Exclusion Criteria  
Patients are excluded from entering the study if they:  
1. require concomitant cardiac procedure(s);  
2. have a haemoglobin level < 90g/L;  
3. are pregnant; have received previous cardiac surgery;  
4. are unable to stop currently prescribed treatment affecting clotting;  
5. have a haematological condition that would affect participation in the trial;  
6. have infective endocarditis;  
7. are prevented from having red blood cells and blood products according to a 
system of beliefs;  
8. or have any other medical, psychiatric and or social reason that precludes 
participation. 
 
Eligibility Check 
Participants have their eligibility checked and confirmed within the 14 days prior to 
surgery. Eligibility is confirmed by one of the three operating cardiac surgeons who 
are clinical investigators for this trial.  
 
Interventions 
Manubrium-limited ministernotomy (intervention): 
Manubrium-limited mini-ministernotomy (intervention arm) is performed using systemic 
normothermia. An incision is made from the sternal notch to the second intercostal 
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space. The manubrium is divided longitudinally in the midline. The sternum is then 
transected in both directions from the second intercostal spaces until the midline 
incision is reached, creating a V-shape. This procedure is depicted in Figure 1. Aortic 
cannulation is through the ascending aorta. As the right atrium is poorly visualized 
with this technique, venous cannulation is percutaneous through the femoral vein 
(using a Seldinger technique guided by transoesophageal ECHO). Vacuum assist is 
used as necessary to aid venous drainage. Antegrade cardioplegia is used for 
myocardial protection and venting is via the pulmonary artery. A transverse 
aortotomy is performed, followed by standard aortic valve insertion using interrupted 
nonpledgeted braided sutures. The aortotomy is closed in a single or double layer. 
One pericardial drain and ventricular pacing wires are placed in all patients. Atrial 
wires are placed if needed. These steps are performed prior to removing the 
crossclamp to facilitate the view of the right atrium and ventricle. Sternal closure is 
with two wires in the manubrium and two wires from the body of the sternum up to 
the manubrium. 
 
 
Insert Figure 1.   
 
 
Conventional Median Sternotomy (control): 
For the conventional technique, a standard median sternotomy is performed using 
systemic normothermia. Cannulation is via the ascending aorta with two-stage right 
atrial cannulation for venous drainage. Venting of the left ventricle is achieved via 
tha pulmonary artery and myocardial protection is with cold blood antegrade 
cardioplegia. All valves are inserted using interrupted sutures. 
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During the trial, both operations are performed in accordance with an agreed and 
standardised anaesthetic protocol. Patients are given lorazepam as a pre-
medication, followed by anaesthesia with propofol, fentanyl, rocuronium bromide 
and morphine. All patients are given a total dose of tranexamic acid (TXA)at 
30mg/kg. Where patients have a pre-surgical creatinine >200 mmol/l, the dose of TXA 
is halved to 15mg/kg. Prior to cardiopulmonary bypass, systemic anticoagulation is 
achieved with heparin given at a dose that achieves an activated clotting time 
(ACT) of greater than 400 seconds. Fresh Frozen Plasma (FFP) is administered if the 
target ACT is not reached. During cardiopulmonary bypass, Hb is kept at 60g/L or 
above. Haemofiltration followed by red blood cell transfusion may be required to 
achieve this. Following CPB, protamine will be administered to reverse heparin, 
according to the dose of heparin given. Blood products may be used intra 
operatively in the presence of excessive blood loss. Red blood cell salvage will be 
used in all patients. 
 
All patients have the new aortic valve assessed at the end of surgery using a 
transoesophageal echocardiogram (TOE). Details of this, as well as any additional 
surgical intervention, including conversion to conventional sternotomy from 
manubrium-limited sternotomy, and any further TOE are recorded.  
 
Post-operative warfarin and aspirin administration 
Post-operatively, all patients having a biological prosthesis begin 75mg aspirin on the 
morning of the day following surgery. All patients having a mechanical prosthesis 
commence on warfarin on the evening of the day following surgery.  
 
Post-operative aAssessments and pProcedures 
The post-operative period (and trial protocol in relation to red blood cell and other 
blood product transfusion) begins once the patient has been admitted to Cardiac 
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Intensive Care Unit (CICU). Residual blood after cardiopulmonary bypass that has 
been bagged may all be given as a transfusion intravenously; the transfusion of this 
residual blood is commenced prior to CICU admission. 
 
Blood and blood product usage following surgery 
The post-operative red blood cell transfusion and blood product transfusion processes 
for this trial begin from the point of admission to the Cardiac Intensive Care Unit 
(CICU). All residual blood from the CPB reservoir and cell salvaged blood is returned 
to the patient; the following transfusion processes are implemented following 
complete transfusion of this blood, and continue until a patient is discharged 
following their index operation.   
Trial patients receive a red blood cell transfusion if at least one of the following criteria 
are met: 
 their Hb is <80 g/L  
 a diagnosis of post-operative bleeding is made as defined by ≥400ml/h blood 
loss or ≥100ml/h for ≥ 4 hours with Hb ≥80g/L. 
 blood loss leading to haemodynamic instability occurs irrespective of 
thromboelastography (TEG) and clotting profile results.  
 
Trial patients receive a blood product transfusion if both of the following criteria are 
met: 
 a diagnosis of post-operative bleeding occurs as defined by ≥400ml/h blood 
loss or ≥100ml/h for ≥ 4 hours. 
 TEG or coagulation guided transfusion is indicated 
Clinicians are able to transfuse, or decide not to transfuse, in violation of the protocol 
parameters; their reason for doing so is recorded.  
 
Outcomes  
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Primary Outcome 
The primary outcome of the trial is the proportion of patients who receive a red blood 
cell transfusion post-operatively and within 7 days of AVR surgery.  
 
Secondary Outcomes 
Secondary outcomes for this trial are: 
 the proportion of patients who receive a red blood cell transfusion and during 
the intra-operative period, and the entire postoperative hospital stay,  
 the mean number of red blood cell units transfused during the intra-operative 
period, post-operative period (from arrival at CICU towithin the  7 days 
following AVR surgery) and the entire postoperative hospital stay,  
 the proportion of patients receiving platelet transfusion or receiving fresh 
frozen plasma transfusion during the intra-operative period, within the 7 days 
following AVR surgery and during the entire hospital stay,  
 the mean number of platelet transfusions or fresh frozen plasma 
transfusionsunits transfused received during the intra-operative period, within 
the 7 days following AVR surgery and during the entire hospital stay,  
 mean postoperative blood loss (mls) measured from chest drains at 6 and 12 
hours, and at the time of drain removal, following AVR surgery,  
 operative success as defined by transthoracic echocardiographic assessment 
of left ventricular function, and degree of aortic regurgitation, within 6 weeks 
of AVR surgery,  
 mean post–operative changes in haemoglobin (Hb) within the index hospital 
stay,  
 mean post-operative changes in inflammatory markers on admission to CICU 
and on day 1 following AVR surgery,  
 proportion of patients reporting moderate or severe post-operative sternal 
wound pain, measured daily using an 11 point numerical rating scale 
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developed by the trial team, until patient is fit for hospital discharge, and at 6 
and 12 weeks following AVR surgery, 
 rates of re-operation following index AVR surgery until 12 weeksrates,  
 rate of conversion to conventional AVR during index surgery,   
 changes in forced expiratory volume and forced vital capacity on days 3 and 
4 and at 6 weeks pulmonary function tests (PFTs) following AVR surgery,   
 EuroQOL EQ-5D-3L (2019) scores, captured at baseline and on day 2, and 6 
weeks and 12 weeks following AVR surgery, will be converted to health status 
scores using the value set (time trade off) (210) and provide patient-level 
QALY estimates  as a health outcome (221). The EQ-5D-3L is a validated, self-
reported outcome measure consisting of five dimensions: mobility, self-care, 
usual activity, pain / discomfort, anxiety / depression. Each dimension has 
three levels of response.  
 mean time at to which patients are fit for discharge from hospital following 
AVR surgery,  
 health care utilisation during hospital stay and following discharge to 12 weeks 
from medical note review, GP records and patient reports,  
 cost and cost effectiveness analyses estimated from QALY estimates and 
health care utilisation valued using national reference costs to 12 weeks, 
 rates of related adverse events during the 12 weeks following surgery profiles 
including severity.  
 
Participant tTimeline 
Patients are followed for 12 weeks with follow up at 6 weeks and 12 weeks after 
discharge from hospital following their index AVR operation. Figure 2 provides a flow 
chart of the patient pathway in the trial.  
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Sample size calculation 
This trial will determine if manubrium-limited ministernotomy is an appropriate clinical 
alternative to the existing operation (conventional sternotomy) in terms of red blood 
cell transfusion requirements in the seven days following index surgery. Currently, 
there is clinical and policy equipoise with no intention to extend the use of the new 
procedure until high quality RCT evidence is available.  
 
Using Fisher’s Exact test, 90% power, 5% alpha, 270 patients are required to detect a 
17% reduction in the proportion of patients requiring RBC transfusion (13% compared 
with 30%), using a two-sided test. Recruitment will continue until the target sample size 
is reached and 270 patients are contributing to the primary outcome. 
 
Recruitment  
Patients undergoing isolated AVR surgery will be identified at the point of referral or 
from the inpatient waiting list by the clinical team, and approached by a member of 
the research team about participation in MAVRIC. Patients will be consented by a 
Consultant Cardiothoracic Surgeon or a Surgical Registrar.   
 
Allocation  
Following consent, eligible patients are randomised to receive AVR by manubrium-
limited ministernotomy or by conventional sternotomy following confirmation of 
eligibility. Randomisation is made using a permuted block randomisation, stratified by 
logistic EuroSCORE (2321) (low risk 0-3.50%, moderate risk 3.51-7.5% and high risk 
>7.5%) and by pre-operative Hb (90–125 g/L, 126– 140 g/L, >140 g/L). A web-based 
randomisation system, managed by Durham Clinical Trials Unit ensures concealment 
of allocation.  
 
Blinding 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 MAVRIC 18 
This is a single blind trial. Patients are not informed of the type of sternotomy they are 
planned to receive, or do receive, until completion of the pain assessment on day 2 
following their operation. To enable blinding post-operatively, all patients have a trial 
specific opaque dressing applied to their sternal wound, and to their groin.  
 
Measures Taken to Avoid Bias 
This trial incorporates a number of methods to avoid bias.  
 Concealment of allocation will be achieved through a web-based randomisation 
system, described above, managed by Durham Clinical Trials Unit. Named clinical 
research team members enter a minimum data set per patient before individual 
allocation to treatment is provided.  
 Three consultant cardiothoracic surgeons perform all operations as part of this trial. 
Each is expert in both techniques and does not delegate to other trainee or 
consultant surgeons.  
 Criteria for blood and blood product transfusions are detailed in the protocol and 
followed for all patients. Clinical staff in all cardiothoracic wards follow this 
protocol. Where clinical need requires blood to be given outside of the protocol, 
this is documented and described. The trigger for all transfusions is recorded.   
 Patients are blind to the sternotomy procedure, both planned and received, for 
two days following their index surgery. All have opaque dressing applied to both 
the sternum and the groin to facilitate blinding; these are only removed, and the 
patient informed, following their day two trial assessments unless clinical need 
requires earlier removal. Sternal wound pain is assessed using an eleven point 
numerical rating scale, with all analgesic medication taken in the preceding four 
hours recorded.  
 Fitness for discharge is measured using defined physiotherapy and clinical criteria; 
these are assessed daily from day three by a research team physiotherapist and 
by the surgical research team. The date that both physiotherapy and clinical 
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criteria are met is defined as the date the patient is fit for discharge. The date of 
actual discharge is also recorded. 
 Where patients choose to withdraw from the study prior to seven days following 
their index surgery, permission is sought to continue data collection to support 
analysis of the primary endpoint.  
 
Data collection methods 
Baseline Assessments 
In addition to usual care procedures, baseline assessments take place following 
consent and prior to surgery. 
 
Cardiovascular and significant current and past medical history 
A full medical history is recorded for each patient at baseline and includes details of 
all clinically significant past medical conditions and all clinically significant on-going 
medical conditions including full cardiovascular history.  
 
Physical assessment 
A physical assessment of height (measured in cm), and weight (measured in kg) 
determines Body Mass Index.  
 
Current medications 
A full list of the generic names of relevant medications taken by the patient is 
recorded within 14 days before surgery. The information includes frequency and 
dose. Changes or additions are recorded from baseline until the 12-week follow up 
visit. 
 
For patients in both trial arms, pre-operative antiplatelet drugs (including clopidogrel 
and aspirin), and anti-coagulants (including heparin and warfarin) are discontinued 5 
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days prior to surgery.  The exception is aspirin, which is stopped 5 days prior to surgery 
where possible, however, continuation until the day of surgery does not exclude a 
patient from the trial, and is recorded. These drugs may be re-started following 
surgery at the discretion of the clinical team. Dates for re-starting medications are 
recorded.  
 
INR checks for warfarin patients 
Patients on warfarin have their INR checked as part of routine care on admission to 
hospital for their index surgery. Where an INR is ≤1.5, the patient proceeds to surgery. 
Where a patient’s INR is >1.5, appropriate treatment may be given and surgery may 
need to be delayed. The INR for patients taking warfarin must be ≤1.5 prior to surgery.  
 
Demographic information 
The following demographic data is recorded: 
• age  
• gender 
• ethnicity 
 
Blood Tests 
Blood tests are taken within 14 days prior to surgery and prior to randomisation:  
• U&Es (Sodium, Potassium, Creatinine, Urea), 
• Pregnancy test,  
• Full Blood Count (Haemoglobin, Haematocrit, Platelets, White Cell Count), 
• Coagulation screen (PT, PTR APTT, APTTR), 
• Inflammatory markers (NT-proBNP, and cytokines). 
 
Out of normal range blood parameters are assessed by the clinical team to confirm 
that there are no clinically significant findings that would affect continuation in the 
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trial. The value of haemoglobin taken up to 14 days pre-surgery is used as a stratifying 
variable for randomisation.  
 
Patients also have blood samples (stored as plasma) taken pre-operatively, on 
admission to CICU and 24 hours post-operatively. These are analysed to explore the 
following null hypotheses:  
1. That there will be no difference between peri-operative inflammatory markers (Il-
1, ILl-6, ILl-8, TNF-αIL-10) and markers of endothelial inflammation (VCAM-1, ICAM-1 
or CD62E) between those undergoing AVR via manubrium-limited ministernotomy 
when compared to AVR via conventional sternotomy. 
2. That there is no correlation between the number and proportion of patients who 
receive a red blood cell transfusion and the number of units transfused and peri-
operative inflammatory markers (Il-1, IlL-6, IlL-8, IL-10TNF-α). 
 
Echocardiogram 
Results from the latest echocardiogram (echo) pre-surgery are recorded. If an echo 
has not been done within 39 weeks (9 months) of consent, this is repeated at 
baseline.  
 
Pulmonary Function Tests 
Pulmonary Function tests of Forced Expiratory Volume (FEV1) and Forced Vital 
Capacity (FVC) are performed at baseline with patients sitting for both assessments. 
These assessments are repeated on days 3 and 4, and at 6 weeks following discharge 
from hospital after their index surgery.  
 
EuroSCORE 
Logistic EuroSCORE (2231) is determined prior to randomisation to be used as a 
stratifying variable, with the score recorded. The elements that determined the 
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logistic EuroSCORE pre-operatively are also recorded. EuroSCORE II (2342) and the 
elements that determine this score are also recorded.  
 
Quality of Life Assessment (EuroQoL EQ-5D-3L (20)) 
Each patient completes the Euro-QoL EQ-5D-3L (2019) questionnaires at baseline. If 
the patient is physically unable to complete the questionnaires, or the assessment is 
being performed over the telephone, the research team administer them to the 
patient, who dictates their answers. The details of who is recording the patient’s 
responses are noted. Questionnaires are repeated at day 2, 6 weeks and 12 weeks (3 
months) following discharge from hospital.  
 
Assessment of Pain 
Pain is assessed within 14 days prior to index surgery using an eleven point numerical 
rating scale. Pain is also assessed post-operatively (daily from post-operative day 2 
until the patient is deemed ‘fit for discharge’, and at follow-up (6 and 12 weeks 
following discharge). 
 
Retention of participants 
Patients who withdraw have all data collected up until the point of withdrawal 
included in the study except where withdrawal is due to a related adverse event (AE) 
in which case the patient is followed until a stable outcome is achieved. 
 
Data management 
The study is managed by the Chief Investigator with support from Durham Clinical 
Trials Unit (DCTU).  
Study data is recorded in each patient’s medical notes before being entered on to 
electronic Case Report Forms (e-CRFs). Data entered into the e-CRF must be 
consistent with the information in the medical notes. Discrepancies are noted and 
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explained. Un-anonymised data is held on site in accordance with local Trust policies. 
Patients are identified by a unique study number at enrolment. All data passed to 
DCTU has patient identifiers removed, except date of birth, gender, ethnicity and 
unique study ID. All data are handled in a confidential manner by DCTU, the research 
team and by members of the DMC and TSC.  
 
Statistical methods  
The null hypothesis is that there will be no difference in the proportion of patients 
receiving red blood cell transfusion after manubrium-limited ministernotomy when 
compared to conventional sternotomy for AVR.   
 
This trial will determine if manubrium-limited ministernotomy is an appropriate clinical 
alternative to the existing operation (conventional sternotomy) in terms of red blood 
cell transfusion requirements in the seven days following index surgery. Analysis of the 
primary endpoint will be conducted using Fisher’s exact test. Sensitivity analysis will 
also be performed for the primary endpoint using a logistic regression model to 
account for potential confounders and stratification factors. Continuous outcomes 
will be analysed using general linear models. Correlation between repeated 
measures per patient will be appropriately accounted for in the linear models where 
applicable. Binary data will be analysed using logistic regression where there are no 
repeated data per patient. Repeated binary data will be analysed using generalised 
estimating equations. Stratification factors and chance baseline imbalances 
following randomisation will be explored for the primary and secondary outcomes. 
 
Analysis will follow intention to treat principles with patients analysed according to the 
surgery allocated by randomisation and irrespective of surgery received, subsequent 
management or events. Every effort will be made to retain and include all patients 
who receive surgery as part of the trial. 
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A prospective economic evaluation is integrated into the trial design and applies an 
NHS perspective to the inclusion of costs. Mechanisms of missingness within the data 
will be explored and multiple imputation methods will be applied to impute missing 
data and minimise bias. Imputation sets will be used in bivariate analysis of costs and 
QALYS to generate incremental cost per QALY estimates and credible intervals (24-
27). It is anticipated that incremental costs and benefits will be captured within the 
trial, although extrapolated economic modelling will be considered if appropriate. 
Findings will be presented on the ICER plane and using Cost-Effectiveness 
Acceptability Curves (CEACs)’. 
Economic analysis will use within trial (stochastic) and, if appropriate, extrapolated 
(probabilistic) models.  Patient level cost data will be estimated by applying national 
reference costs to reported healthcare resource use. Stochastic incremental cost-
effectiveness analysis will be used to estimate the value of manubrium-limited 
ministernotomy in place of conventional sternotomy for AVR, using the cost-QALY 
metric, by generating a bootstrapped Incremental Cost Effectiveness Ratio (ICER) 
plane and Cost-Effectiveness Acceptability Curve (CEAC).   
 
MonitoringGovernance 
The trial is overseen by a Trial Steering Committee, which includes an independent 
chair and two other independent members (one of whom is a patient). In addition 
the trial has a DMC, which meets 6 monthly, and oversees all ethical and safety issues 
in accordance with a study specific DAMOCLES charter (2853) for data monitoring 
committees. All members are independent of the study team, although the Trial 
Manager, Chief Investigator and some other members of the Trial Management 
Group (TMG) attend the open sessions in order to inform the DMC of trial progress.  
 
HarmsReporting of adverse events 
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Adverse Events (AEs) and Serious Adverse Events (SAEs) are recorded and reported 
from the time of index surgery until completion or withdrawal. SAEs are reported 
within 24 hours of the research team becoming aware of the event to the Sponsor. 
Where required, these events undergo expedited reporting to the Research Ethics 
Committee. All AEs are assessed for severity, causality, expectedness and seriousness 
by an Investigator; all are reviewed by the DMC.   
 
Research eEthics aApproval  
This protocol and all trial related documents were originally approved by the National 
Research Ethics Service Committee, North East - Newcastle & North Tyneside 1, in 
March 2014 [IRAS Project 137295; REC Reference 14/NE/0005]. Since initial approval, 
threewo amendments have been made and approved; thus this is version 4 5 of the 
protocol.    
 
Declaration of interests  
No members of the research team, nor any collaborators, have any conflicts of 
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Dissemination  
On-going patient and public involvement informs appropriate methods of 
dissemination to patients. Feedback will be given to national surgical leads via the 
Society for Cardiothoracic Surgeons in Great Britain and Ireland, maximising the 
exposure of findings to cardiac surgeons diagnosing and treating patients requiring 
AVR. 
 
Findings will be presented at national specialist meetings to raise awareness. We will 
engage directly with surgeons and cardiothoracic units around the country sharing 
results. Data will be presented at the annual meeting of the Society for 
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Cardiothoracic Surgeons in Great Britain and Ireland and we anticipate this to be the 
main forum for disseminating findings from this study. 
 
Discussion 
 
This is the first trial to examine aortic valve replacement via manubrium-limited 
ministernotomy versus conventional sternotomy when comparing red blood cell 
transfusion rates following surgery. MAVRIC will determine if manubrium-limited 
ministernotomy should be adopted as best practice for patients requiring AVR 
surgery.  
It was not possible to blind clinicians to the surgical procedure provided, although 
transfusion decisions are protocol-driven and should not be procedure-related. The 
inclusion of patient blinding was in response to a funding panel recommendation: it 
has been possible to implement this through the use of opaque dressing and means 
that patient-reported pain scores at two days will be blinded. We will assess the 
effectiveness of blinding by inviting patients to indicate which treatment they think 
they have received before removing the dressings.  
 
Surgical trials present significant challenges; strengths of this trial include a rigorous 
research design, standardised surgery performed by experienced consultant 
cardiothoracic surgeons, an agreed anaesthetic regimen, patient blinding, and 
consultant-led patient recruitment. Each discipline within the Cardiothoracic Division 
at JCUH is supporting and collaborating with the Chief Investigator. MAVRIC will 
demonstrate that complex surgical trials can be delivered to exemplary standards 
and provide the community with the knowledge required to inform future care for 
patients requiring aortic valve replacement surgery.  
Protocol Version. 
Version 45 
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Trial status 
The trial began recruiting in March 2014; the trial is due to report in 2017.  
List of abbreviations 
AVR – Aortic Valve Replacement 
JCUH – The James Cook University Hospital 
CICU – Cardiac Intensive Care Unit 
TEG – Thromboelastography 
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EA conceived ideas for the study.  All authors contributed to the design and writing of 
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This trial would not be possible without the enthusiasm and commitment of clinicians, 
nurses, professionals and patients within the Cardiothoracic Division and Research 
and Development Department at The James Cook University Hospital and the wider 
cardiothoracic surgical community.  
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Surgeon confirms 
patient’s eligibility
Randomisation 
Patient identified at point of referral or from 
inpatient waiting list and seen by consultant 
cardiac surgeon
Patient randomised to 
receive AVR via 
manubrium-limited 
ministernotomy
Patient randomised to 
receive AVR via 
conventional median 
sternotomy
AVR surgery received
Post-Op Day 1. 
FBC, Coag and inflammatory marker bloods. 
Assess fitness for transfer 
Post-Op Day 2. 
FBC, complete EQ-5D-3L, EQ-VAS 
questionnaires and pain score. Ask patient 
about allocation prior to un-blinding. 
Post-Op Day 3
FBC, PFTs (FEV1 and FVC), pain score. Assess 
fitness for discharge (daily until applicable).  
Post-Op Day 4
FBC, PFTs (FEV1 and FVC), pain score.
Post-Op Day 5 daily until fit for discharge
FBC, pain score
6 week follow up visit
ECHO, PFTs, EQ-5D-3L, EQ-VAS & pain score
12 week follow up (via telephone)
EQ-5D-3L, EQ-VAS and pain score
Admission to CICU. 
Begin MAVRIC blood and blood product 
transfusion protocol. Take FBC, Coag and 
Inflamamtory marker blood
Written consent 
obtained and baseline 
assessments
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